McK6A1

McK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases[1].

12352209

Amyloid-β

Neuronal Signaling

Neuroscience-Neurodegeneration

Neurological Disease

N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCCC[C@@H](C(NNC(C1=CC(NC(C(N[C@H](C(N[C@H]2CC3=CC=C(O)C=C3)=O)CCCCN)=O)=O)=CC=C1OC)=O)=O)N)=O)CCCCN)=O)CC4=CC=C(O)C=C4)=O)CC5=CNC6=CC=CC=C56)=O)CC(C)C)=O)[C@@H](C)O)=O)CCCNC2=O

C71H99N17O16

1446.65

[1]Lu J, et al., Structure-Based Peptide Inhibitor Design of Amyloid-β Aggregation. Front Mol Neurosci. 2019 Mar 4;12:54.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10876/

Peptides

No Development Reported